Houston Methodist medication policy denotes Neulasta as the preferred pegfilgrastim product. Udenyca is the preferred biosimilar product if the third party payor will only cover a biosimilar. Preferred products are first-line preferred agents for use, however, alternative product selection is permitted if mandated by third party payor coverage.
Consults, protocols, and therapeutic interchanges
Additional information
Houston Methodist medication policy denotes Neulasta as the preferred pegfilgrastim product. Udenyca is the preferred biosimilar product if the third party payor will only cover a biosimilar. Preferred products are first-line preferred agents for use, however, alternative product selection is permitted if mandated by third party payor coverage.